STOCK TITAN

EyePoint Pharmaceuticals, Inc. - EYPT STOCK NEWS

Welcome to our dedicated page for EyePoint Pharmaceuticals news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint Pharmaceuticals stock.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts. The company is committed to developing and commercializing ophthalmic products aimed at treating serious retinal diseases. EyePoint leverages its proprietary Durasert® technology, a sustained intraocular drug delivery system, to create treatments that can provide continuous therapeutic effects for extended periods.

EyePoint Pharmaceuticals has made significant strides in the field of retinal disease treatments. Its lead product candidate, DURAVYU™ (previously known as EYP-1901), is an investigational treatment for VEGF-mediated retinal diseases. This product combines vorolanib, a selective tyrosine kinase inhibitor, with the Durasert® technology to offer sustained delivery and improved patient outcomes. DURAVYU™ is currently undergoing clinical trials for conditions such as wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR).

The company also has several other promising candidates in its pipeline, including EYP-2301, a TIE-2 agonist, and razuprotafib, formulated with Durasert® technology to potentially enhance treatment outcomes for serious retinal diseases.

EyePoint’s innovative approach extends beyond product development to strategic partnerships and collaborations. The company has secured exclusive licenses for vorolanib from Equinox Sciences for all ophthalmic uses outside of China, Macao, Hong Kong, and Taiwan. Additionally, EyePoint has FDA-approved products such as RETISERT® and YUTIQ® that are based on its proprietary drug delivery technology.

Financially, EyePoint Pharmaceuticals has shown a solid performance with total net revenue of $46.0 million for the year ended December 31, 2023, compared to $41.4 million for the previous year. This growth is driven primarily by revenues from royalties and collaborations. The company has also strengthened its financial position with $331.1 million in cash, cash equivalents, and marketable securities as of December 31, 2023.

EyePoint is dedicated to driving innovation in ophthalmology and improving the quality of life for patients with serious eye conditions. With a focus on advancing its robust pipeline through clinical development, EyePoint Pharmaceuticals continues to make headway in addressing unmet medical needs in retinal diseases.

Rhea-AI Summary
EyePoint Pharmaceuticals, Inc. will present a company overview at the Jefferies Healthcare Conference on June 7, 2023. The presentation will be available via webcast and archived replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.6%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.37%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.73%
Tags
-
Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced a conference call and live webcast set for May 3, 2023, at 8:30 a.m. ET to report its first-quarter 2023 financial results and discuss recent corporate developments. The event will provide investors an opportunity to gain insights into the company's performance and strategic initiatives. EyePoint is focused on developing therapeutics for serious eye disorders, leveraging its proprietary Durasert technology for sustained drug delivery. Among its pipeline products is EYP-1901, currently in Phase 2 clinical trials, which targets intravitreal anti-VEGF treatment. EyePoint’s products, including YUTIQ, have previously gained FDA approval, showcasing its commitment to advancing eye care solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.48%
Tags
conferences earnings
-
Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced on April 17, 2023, the grant of non-statutory stock options for 13,000 shares to two new employees as part of an inducement package outside its 2016 Long-Term Incentive Plan. The options were granted on April 14, 2023, with an exercise price set at $4.33 per share, reflecting the stock’s closing price on that date. The options have a ten-year term and vest over four years, beginning with 25% vesting after one year, followed by monthly vesting thereafter. This move is in accordance with NASDAQ Listing Rule 5635(c)(4) and aims to enhance recruitment efforts by offering competitive compensation packages to new talent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.01%
Tags
none
Rhea-AI Summary

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) has successfully completed enrollment in its Phase 2 clinical trial, DAVIO 2, evaluating EYP-1901 for wet age-related macular degeneration (AMD). The trial exceeded its goal by enrolling 160 patients, with top-line data expected in Q4 2023. EYP-1901 aims to provide a six-month maintenance treatment option, addressing the significant treatment burden faced by wet AMD patients. The drug leverages EyePoint's Durasert technology for sustained delivery and has shown promising Phase 1 results, including a stable safety profile and visual acuity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.12%
Tags
-
Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced positive scientific findings to be presented at the 2023 ARVO Annual Meeting. Key highlights include the neuroprotective effect of vorolanib in EYP-1901, demonstrating potential against retinal degeneration in a validated model. Additionally, findings from the CALM registry indicate effective control of inflammation in chronic posterior segment uveitis using YUTIQ. Presentations will cover preclinical data and clinical outcomes, including the Phase 1 DAVIO trial results showing a significant reduction in the need for anti-VEGF injections. The meeting takes place from April 23-27, 2023, in New Orleans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
conferences
-
Rhea-AI Summary

EyePoint Pharmaceuticals announced its financial results for 2022, reporting a 13% increase in net product revenues to $39.9 million. The company has two Phase 2 clinical trials in progress for EYP-1901, targeting wet AMD and NPDR, with topline data expected by year-end 2023. In addition, operating expenses rose to $141 million, primarily due to a $20.7 million impairment charge from DEXYCU. EyePoint has $144.6 million in cash and investments, projected to fund operations into 2H 2024. The company also plans to disclose preclinical data at the upcoming 2023 ARVO Annual Meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.83%
Tags
Rhea-AI Summary

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), based in Watertown, Mass., announced participation in two upcoming conferences. The Cowen 43rd Annual Healthcare Conference will feature a fireside chat on March 6, 2023, at 9:10 a.m. ET. The Guggenheim 4th Annual Healthy Altitudes Summit is scheduled for March 15, 2023, at 9:00 a.m. ET. Investors can access webcasts and archived replays via the company’s website. EyePoint specializes in developing therapeutics for serious eye disorders, utilizing its Durasert® technology for sustained drug delivery, including the investigational EYP-1901, currently in Phase 2 trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
conferences

FAQ

What is the current stock price of EyePoint Pharmaceuticals (EYPT)?

The current stock price of EyePoint Pharmaceuticals (EYPT) is $7.1 as of December 20, 2024.

What is the market cap of EyePoint Pharmaceuticals (EYPT)?

The market cap of EyePoint Pharmaceuticals (EYPT) is approximately 485.9M.

What does EyePoint Pharmaceuticals, Inc. (EYPT) specialize in?

EyePoint Pharmaceuticals specializes in developing and commercializing ophthalmic products aimed at treating serious retinal diseases using its proprietary sustained intraocular drug delivery system, Durasert®.

What is DURAVYU™?

DURAVYU™ (EYP-1901) is EyePoint's lead product candidate, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib with Durasert® technology.

Where is EyePoint Pharmaceuticals headquartered?

EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts, USA.

What are the key products in EyePoint's pipeline?

Key products in EyePoint's pipeline include DURAVYU™ (EYP-1901), a TIE-2 agonist EYP-2301, and razuprotafib, all utilizing the Durasert® technology.

How did EyePoint Pharmaceuticals perform financially in 2023?

For the year ended December 31, 2023, EyePoint reported total net revenue of $46.0 million, driven by revenues from royalties and collaborations.

What is the Durasert® technology?

Durasert® is EyePoint's proprietary sustained intraocular drug delivery system designed to provide continuous therapeutic effects for extended periods.

Has EyePoint Pharmaceuticals received FDA approval for any products?

Yes, EyePoint has received FDA approval for products like RETISERT® and YUTIQ®, which are based on its Durasert® drug delivery technology.

What are the geographical operational footprints of EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals operates in the U.S., China, and the UK.

What is EyePoint's strategy for future growth?

EyePoint's strategy involves advancing its clinical pipeline, securing strategic partnerships, and leveraging its proprietary Durasert® technology to address unmet medical needs in serious retinal diseases.

How does EyePoint Pharmaceuticals generate revenue?

EyePoint generates revenue primarily from royalties, collaborations, and product sales.

EyePoint Pharmaceuticals, Inc.

Nasdaq:EYPT

EYPT Rankings

EYPT Stock Data

485.95M
65.07M
1.14%
93.48%
14.47%
Biotechnology
Laboratory Analytical Instruments
Link
United States of America
WATERTOWN